Expresión de O6-metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiforme

Background: Patients with Glioblastoma multiforme (GBM) have a five years survival of less than 5%, but the response to chemotherapy with alkylating agents can vary depending on the methylation status of O6-methylguanine-DNA-methyltransferase (MGMT). Genetic testing has limitations for routine use,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiménez,Daniel, Matamala,José Manuel, Chiti,Alessandra, Vergara,Carmen, Tissera,Claudia, Melo,Rómulo, Cartier,Luis
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2018
Materias:	Glioblastoma Immunohistochemistry O6-Methylguanine-DNA-Methyltransferase Prognosis
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000100007
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872018000100007
record_format	dspace
spelling	oai:scielo:S0034-988720180001000072018-05-11Expresión de O6-metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiformeJiménez,DanielMatamala,José ManuelChiti,AlessandraVergara,CarmenTissera,ClaudiaMelo,RómuloCartier,Luis Glioblastoma Immunohistochemistry O6-Methylguanine-DNA-Methyltransferase Prognosis Background: Patients with Glioblastoma multiforme (GBM) have a five years survival of less than 5%, but the response to chemotherapy with alkylating agents can vary depending on the methylation status of O6-methylguanine-DNA-methyltransferase (MGMT). Genetic testing has limitations for routine use, while immunohistochemistry (IHC) offers a fast and affordable technique but with heterogeneous results in the literature. Aim: To evaluate MGMT expression by IHC in tumor tissue of Chilean patients with GBM. Material and Methods: Tumor samples of 29 patients with a pathological diagnosis of GBM were studied. We performed IHC staining and manual analysis of positive and negative cells for MGMT expression. A cut-off of at least 10% of cells expressing MGMT was used. Demographic and clinical features of patients were obtained from clinical records. Results: The median number of cells counted per case was 692 (interquartile range [IQR] 492-928). Fifteen cases (52%) were positive for MGMT expression. Median overall survival was 5.3 months (IQR 3.4-12-8). The effect of MGMT expression on the therapeutic response was not studied since only 3 patients received chemotherapy. Conclusions: Our results are similar to international reports, but we were not able to determine the association between MGMT expression and therapeutic response.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.146 n.1 20182018-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000100007es10.4067/s0034-98872018000100007
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Glioblastoma Immunohistochemistry O6-Methylguanine-DNA-Methyltransferase Prognosis
spellingShingle	Glioblastoma Immunohistochemistry O6-Methylguanine-DNA-Methyltransferase Prognosis Jiménez,Daniel Matamala,José Manuel Chiti,Alessandra Vergara,Carmen Tissera,Claudia Melo,Rómulo Cartier,Luis Expresión de O6-metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiforme
description	Background: Patients with Glioblastoma multiforme (GBM) have a five years survival of less than 5%, but the response to chemotherapy with alkylating agents can vary depending on the methylation status of O6-methylguanine-DNA-methyltransferase (MGMT). Genetic testing has limitations for routine use, while immunohistochemistry (IHC) offers a fast and affordable technique but with heterogeneous results in the literature. Aim: To evaluate MGMT expression by IHC in tumor tissue of Chilean patients with GBM. Material and Methods: Tumor samples of 29 patients with a pathological diagnosis of GBM were studied. We performed IHC staining and manual analysis of positive and negative cells for MGMT expression. A cut-off of at least 10% of cells expressing MGMT was used. Demographic and clinical features of patients were obtained from clinical records. Results: The median number of cells counted per case was 692 (interquartile range [IQR] 492-928). Fifteen cases (52%) were positive for MGMT expression. Median overall survival was 5.3 months (IQR 3.4-12-8). The effect of MGMT expression on the therapeutic response was not studied since only 3 patients received chemotherapy. Conclusions: Our results are similar to international reports, but we were not able to determine the association between MGMT expression and therapeutic response.
author	Jiménez,Daniel Matamala,José Manuel Chiti,Alessandra Vergara,Carmen Tissera,Claudia Melo,Rómulo Cartier,Luis
author_facet	Jiménez,Daniel Matamala,José Manuel Chiti,Alessandra Vergara,Carmen Tissera,Claudia Melo,Rómulo Cartier,Luis
author_sort	Jiménez,Daniel
title	Expresión de O6-metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiforme
title_short	Expresión de O6-metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiforme
title_full	Expresión de O6-metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiforme
title_fullStr	Expresión de O6-metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiforme
title_full_unstemmed	Expresión de O6-metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiforme
title_sort	expresión de o6-metilguanina-adn-metiltransferasa (mgmt) en pacientes chilenos con glioblastoma multiforme
publisher	Sociedad Médica de Santiago
publishDate	2018
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000100007
work_keys_str_mv	AT jimenezdaniel expresiondeo6metilguaninaadnmetiltransferasamgmtenpacienteschilenosconglioblastomamultiforme AT matamalajosemanuel expresiondeo6metilguaninaadnmetiltransferasamgmtenpacienteschilenosconglioblastomamultiforme AT chitialessandra expresiondeo6metilguaninaadnmetiltransferasamgmtenpacienteschilenosconglioblastomamultiforme AT vergaracarmen expresiondeo6metilguaninaadnmetiltransferasamgmtenpacienteschilenosconglioblastomamultiforme AT tisseraclaudia expresiondeo6metilguaninaadnmetiltransferasamgmtenpacienteschilenosconglioblastomamultiforme AT meloromulo expresiondeo6metilguaninaadnmetiltransferasamgmtenpacienteschilenosconglioblastomamultiforme AT cartierluis expresiondeo6metilguaninaadnmetiltransferasamgmtenpacienteschilenosconglioblastomamultiforme
_version_	1718436984168382464

Expresión de O6-metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiforme

Ejemplares similares